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Abstract
Trib2 pseudokinase is involved in the etiology of a number of cancers including leukaemia, melanoma, ovarian, lung
and liver cancer. Both high and low Trib2 expression levels correlate with different types of cancer. Elevated Trib2
expression has oncogenic properties in both leukaemia and lung cancer dependent on interactions with proteasome
machinery proteins and degradation of transcription factors. Here, we demonstrated that Trib2 deﬁciency conferred a
growth and survival advantage both at steady state and in stress conditions in leukaemia cells. In response to stress,
wild type leukaemia cells exited the cell cycle and underwent apoptosis. In contrast, Trib2 deﬁcient leukaemia cells
continued to enter mitosis and survive. We showed that Trib2 deﬁcient leukaemia cells had defective MAPK
p38 signalling, which associated with a reduced γ-H2Ax and Chk1 stress signalling response, and continued
proliferation following stress, associated with inefﬁcient activation of cell cycle inhibitors p21, p16 and p19.
Furthermore, Trib2 deﬁcient leukaemia cells were more resistant to chemotherapy than wild type leukaemia cells,
having less apoptosis and continued propagation. Trib2 re-expression or pharmacological activation of p38 in Trib2
deﬁcient leukaemia cells sensitised the cells to chemotherapy-induced apoptosis comparable with wild type
leukaemia cells. Our data provide evidence for a tumour suppressor role of Trib2 in myeloid leukaemia via activation of
p38 stress signalling. This newly identiﬁed role indicates that Trib2 may counteract the propagation and chemotherapy
resistance of leukaemia cells.
Introduction
The Tribbles pseudokinases (Trib1, Trib2 and Trib3)
are multifaceted signalling mediators controlling funda-
mental biological processes, including cell proliferation
and survival, in both physiological and disease condi-
tions1. Tribbles are inducible genes, modulated by a wide
range of mitogens and stressors, and associated with
downstream regulation of key signalling pathways,
including AKT, ATF4, NF-kB and the MAPKs2–6. TRIB2
protein oscillates during cell cycle phases and induces the
nuclear protein turnover of the dual speciﬁcity phospha-
tase and positive cell cycle mitotic regulator CDC25C7.
Tribbles are newly recognised regulators of normal and
malignant haemopoiesis8,9. Whilst TRIB2 levels are low in
myeloid cells at steady state8, TRIB2 has been shown to
regulate activation and inﬂammatory functions of human
monocytes and macrophages3,10,11. Recent investigations
showed that Trib2 is required for normal T-cell and
erythroid development12,13. Trib2 has been shown to
interact with different MAPK kinases (MAPKK), such as
MEK1 and MKK7, and to either promote or inhibit
MAPK cascade activation in distinct cellular contexts4,11.
Trib2 was ﬁrst identiﬁed as an oncogene in acute
myeloid leukaemia14. We have previously shown that
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Trib2 leukaemogenic potential relies on the ability to
promote proteasomal dependent degradation of the
tumour suppressor transcription factor CCAAT/enhan-
cer-binding protein α (C/EBPα) and reported elevated
TRIB2 expression in a subset of human myeloid leukae-
mia patients with dysregulated C/EBPα proﬁle and mixed
myeloid/T-lymphoid phenotype14,15. Further studies have
associated high and low levels of TRIB2 with leukaemia
subtypes with distinct genetic backgrounds. TRIB2
expression is positively associated with leukaemia patients
that have FLT3 mutated t(15;17) genetics8, and with
patients with elevated BCL2 expression46, and is nega-
tively associated with leukaemia patients that have NPM1
and FLT3 mutations16. It has also been shown that the
absence of Trib2 accelerated NOTCH1-driven T-cell
leukaemia development12,17. Both high and low TRIB2
expression levels were shown to be associated with dis-
tinct human T-cell leukaemia phenotypes12.
The physiological role of Trib2 in myeloid leukaemia is
not well understood. We previously showed that ectopic
Trib2 expression cooperates with Homeobox transcrip-
tion factor Hoxa9 to accelerate myeloid leukaemia
development in mice18. We and others have shown that
expression of TRIB2 is driven by several transcription
factors including NOTCH119,20, TAL121, PITX122,
MEIS123,24 and E2F125. The knockdown of TRIB2 in
leukaemia cells led to leukaemia cell death21,25. However,
low TRIB2 expression is associated with subgroups of
myeloid leukaemia. It is not understood how the absence
of Trib2 expression affects myeloid leukaemia.
Deregulation of the HOX genes occurs in ~70% of
myeloid leukaemias. Indeed HOXA9 alone is over-
expressed in over 50% of acute myeloid leukaemia
patients and correlates with poor prognostic outcome26,27.
Here we used the oncofusion gene NUP98/HOXA9 (NH9)
as a deregulated HOX myeloid leukaemia model28,29 to
investigate the effects of Trib2 deﬁciency in leukaemia
cells. We showed that the absence of Trib2 does not
impede the ability of NH9 to drive transformation.
However, Trib2 deﬁciency enhanced myeloid leukaemia
cell proliferation and survival in both steady state and
stress conditions. Trib2 deﬁcient leukaemia cells had
impaired MAPK stress responses, evaded cell cycle
checkpoint control mechanisms, and resisted
chemotherapy-induced apoptosis. Our data identify Trib2
as a central regulator of p38-mediated stress signalling
pathways and leukaemia cell cycle control.
Results
Trib2’s dispensability for NH9-initiated myeloid leukaemia
The impact of Trib2 deﬁciency in myeloid leukaemia is
not well understood. To address this, we investigated the
ability of NH9 oncofusion to transform wild type (WT)
and Trib2 knockout (Trib2−/−) haemopoietic stem and
progenitor cells (HSPCs) (S1A). HSPCs were isolated
from WT and Trib2−/−mice and transduced with NH9 or
empty vector control MigR1 retrovirus (S1B). In vitro
myeloid cell transformation was assessed by serial
replating ability in a colony forming cell (CFC) assay
(S1A). WT and Trib2−/− MigR1 control groups failed to
replate after the second round of CFC, whereas WT and
Trib2−/− NH9 HSPCs formed colonies up to the fourth
replating indicative of cell transformation (Fig. 1a and
S1C). Moreover, both WT and Trib2−/− HSPCs trans-
duced with NH9 and maintained in liquid culture (LC)
conditions outgrew MigR1 controls and untransduced
cells, as indicated by the increase in the fraction of GFP-
expressing cells over time (S1D-E). To assess the self-
renewal capability of NH9 in the absence of Trib2, a
feature of leukaemic stem cells, we analysed the mRNA
expression of Hoxa9, Hoxa7, Meis1, Runx1, Bm1, Sox4
and Smad730–32, in MigR1 or NH9 transduced WT and
Trib2−/− HSPCs 48 h post-transduction (Fig. 1b). Equal
transduction levels and self-renewal proﬁles of NH9
expressing cells was conﬁrmed by upregulation of the
known target genes Hoxa7 and Hoxa9 in the WT and
Trib2−/− cells. Gene expression analysis of Runx1, Bm1,
Sox4 and Smad7 revealed no differences between the WT
and Trib2−/− NH9 HSPCs or compared to MigR1 con-
trols (Fig. 1b). Moreover, basal expression of Hox genes
was equivalent between WT and Trib2−/− MigR1 control
cells. These data indicate that Trib2 is not required for
NH9-mediated transformation of HSPCs into myeloid
leukaemia cells. To conﬁrm leukaemic stem cell proper-
ties of the WT and Trib2−/− NH9 expressing cells we
analysed leukaemic cell surface marker expression33by
ﬂow cytometry (Fig. 1c–g and S2A). Interestingly, the
proportion of c-Kit+ cells, and the Lineage(Lin)-Sca1-
CD11b+c-Kit+ fraction were higher in the Trib2 deﬁ-
cient cells compared to the WT NH9 cells (Fig. 1c–e).
Similarly, Lin-Sca1-CD127-c-Kit+CD34+/lowCD16/32+
cells, previously identiﬁed as L-GMP (leukaemic granu-
locyte macrophage progenitors34), were increased in the
Trib2−/− NH9 compared to the WT NH9 cells (Fig. 1f, g
and S2B). Overall these results suggest that Trib2 deﬁ-
cient cells retain higher leukaemic stem cell potential.
Trib2 deﬁciency promotes the propagation and survival of
leukaemia cells
To determine the impact of Trib2 deﬁciency on the
growth properties of myeloid transformed cells, we
compared the cell division using the viable dye cell trace
violet (CTV) of MigR1 or NH9 transduced WT and
Trib2−/− HSPCs (from two independent transduction
experiments) that had expanded by CFC assay (GFP
sorted, Fig. 2a, top panels) or in liquid culture (LC) for
2 weeks (unsorted for GFP, Fig. 2a, bottom panels). Our
results showed a higher number of cell divisions in the
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Trib2−/− NH9 cells compared to the WT NH9 cells
(Fig. 2a), indicating that Trib2 negatively regulates mye-
loid leukaemia cell proliferation. WT and Trib2-/- NH9
transduced cells were expanded in LC for several months.
Growth curves conﬁrmed faster proliferation rate and
signiﬁcantly shorter doubling time in Trib2-/- NH9 cells
compared to WT NH9 cells (Fig. 2b, c). To assess the
impact of Trib2 deﬁciency on myeloid leukaemia cell
survival, we measured the level of apoptosis following
growth factor deprivation (GFD) and myeloid leukaemia-
based chemotherapy (daunorubicin (DNR)) in the WT
and Trib2-/- NH9 cells by ﬂow cytometry using Annex-
inV/DAPI staining (Fig. 2d–g). Our analyses showed that
basal levels of apoptosis in Trib2-/- NH9 cells were sig-
niﬁcantly lower compared to the WT NH9 cells (~5 vs.
~20% respectively, Fig. 2d–g 0 h GFD and DMSO treated
samples). Following GFD or DNR treatment, Trib2-/- NH9
cells exhibited lower levels of cell death compared to the
WT NH9 cells (Fig. 2d, e 24 h GFD and Fig. 2f, g DNR
treated samples). These data show that Trib2 deﬁciency
promotes myeloid leukaemia cell proliferation and
survival.
Impaired MAPK activation in the absence of Trib2
Trib2 modulates MAPK signalling3,4,11,12, and MAPKs
are linked to cell proliferation and cancer35,36. Thus, we
interrogated the activation status of the MAPKs ERK, p38
and JNK in WT and Trib2-/- myeloid leukaemia cells.
Western blot analyses showed that Trib2-/- NH9 cells had
lower levels of the phosphorylated (active) forms of ERK1-
2 (Thr202/Tyr204, p-ERK), p38 (Thr180/Tyr182, p-p38)
and JNK (Thr183/Tyr185, p-JNK), compared to the WT
NH9 cells (Fig. 3b). WT and Trib2-/- NH9 cells showed
IL3-dependent growth (Fig. 2b), therefore we tested
MAPK following GFD and re-stimulation with IL3-
containing medium (NH9 medium). We showed that
MAPKs phosphorylation was impaired in Trib2-/- NH9
compared to WT NH9 thus indicating inefﬁcient MAPK
responses in Trib2-/- NH9 (Fig. 3c). Conversely, the
phosphorylation of AKT (Ser473) was similarly activated
following IL3 stimulation in both WT and Trib2-/- NH9
cells (Fig. 3c). We tested the activation of p38 in response
to anisomycin (Ans), a pharmacological activator of the
p38 and JNK pathway, that directly activates MKK6 and
p38 kinases37 (Fig. 3d). The fold increase in p-p38 after
Ans treatment measured by phosphoﬂow cytometry was
reduced in the Trib2-/- NH9 cells compared to the WT
NH9 cell (Fig. 3d). These data showed that Trib2 is
necessary for efﬁcient activation of the p38 kinase.
Overall, these results showed that Trib2 deﬁcient myeloid
leukaemia cells have compromised basal- and induced-
MAPK signalling activation.
Trib2 deﬁciency enables cell cycle progression following
stress
To gain further insight into the mechanism involved in
the enhanced growth and survival of Trib2 deﬁcient leu-
kaemic cells, we assessed the cell cycle control and check
point activation in response to genotoxic stress in WT
and Trib2-/- NH9 cells. Using Ki67/DNA DAPI ﬂow
cytometry staining, we assessed the cell cycle proﬁle of
WT and Trib2-/- NH9 cells following DNR treatment. No
signiﬁcant difference in the cell cycle proﬁles was
observed in untreated WT and Trib2-/- NH9 cells, where
the majority of the cells were in the G1 phase of the cell
cycle (Fig. 4a, b). Following DNR treatment, the majority
of WT NH9 cells were lost from the active G1, S, G2, M
phases and with remaining cells in the GO quiescent
phase of the cell cycle. In contrast, a signiﬁcant proportion
of Trib2-/- NH9 cells were still cycling and with less cells
in the GO quiescent state (Fig. 4a, b). We next assessed
the proportion of cells in the mitotic phase (mitotic index)
by p-HH3/DNA PI staining. In untreated cells, no sig-
niﬁcant differences were observed between the WT and
Trib2-/- NH9 cells. However, a signiﬁcantly higher frac-
tion of p-HH3+ cells was observed in Trib2-/- NH9 cells
compared to WT NH9 cells, following 16, 20 and 24 h
post DNR treatment (Fig. 4c, d). Similarly, a higher frac-
tion of p-HH3+ cells was detected upon GFD condition
in Trib2-/- NH9 (Figure S3). We analysed metaphase
spreads of DNR-treated WT and Trib2-/- NH9 cells by
microscopy to validate the role of Trib2 in mitotic cell
(see ﬁgure on previous page)
Fig. 1 Trib2 is dispensable for NH9 initiated transformation of HSPCs. a CFC assay of WT and Trib2−/− HSPCs retrovirally transduced with MigR1
or NH9 expressing vectors. Graph shows total colony number at CFC1-4. Data are mean of duplicate cultures ± SD; representative of 2 independent
experiments. b Gene expression analysis in WT and Trib2−/− HSPCs retrovirally transduced with MigR1 or NH9 at 48 h post transduction. Data are
means of 3 biological samples (from 1 to 2 mice per biological replicate) ± SD and representative of 2 independent experiments. *P < 0.05, **P <
0.005, ***P < 0.001, using unpaired t-test. c, d Representative dot plots of the CD11b+c-Kit+ fraction (c) and c-Kit expression histograms (d) of WT
and Trib2−/− NH9 cells transformed by CFC assay (top panels) or LC condition (bottom panels), gated through GFP+DAPI-Lin(CD4, CD8, B220,
Ter119)-Sca1- gates. e Graphed percentages are average of 3 independent measurements, as shown (c, d) ±SD. *P ≤ 0.05, **P < 0.005, using unpaired
t-test. f Representative ﬂow cytometry analyses identifying the L-GMP population in WT and Trib2−/− NH9 cells transformed by CFC assay (top panels)
or LC condition (bottom panels), gated through GFP+DAPI-Lin(CD3, CD4, CD8, CD19, B220, Ter119, Gr1)-CD127- and Sca1-c-Kit+(LK) gates. g Graph
shows percentages of the L-GMP cells, as shown (f), in the GFP+DAPI-Lin-fraction. Data are mean of 3 independent measurements ± SD. *P ≤ 0.05,
**P < 0.005, using unpaired t-test
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cycle control following stress stimuli. Similar to p-HH3
mitotic indices, there was an equivalent percentage of
mitotic spreads in the untreated WT and Trib2-/- NH9
cells (Fig. 4e, f). DNR treatment virtually abolished mitotic
entry in the WT NH9 cells, as no mitotic spreads were
observed in any ﬁeld/slide analysed. Conversely, a sig-
niﬁcantly higher proportion of DNR-treated Trib2-/- NH9
were in metaphase compared to WT NH9 cells (Fig. 4e, f).
These data show that Trib2-/- NH9 cells can actively cycle
and undergo mitosis in the presence of stress. These
results indicate a role for Trib2 in the prevention of cell
cycle progression in stress conditions.
Trib2 deﬁciency compromises stress response signalling in
myeloid leukaemia cells
As we have demonstrated a role for Trib2 in leukaemia
cell cycle control in response to stress, we hypothesized
that Trib2 is an inducible component of the cellular stress
response pathways, contributing to check point activation
and survival or death decision. To address this, we
assessed Trib2 mRNA expression levels following GFD
and DNR treatment. In WT NH9 cells, a signiﬁcant
upregulation of Trib2 mRNA expression was observed in
response to DNR treatment (Fig. 5a) and GFD (Fig-
ure S4A). Gene expression analyses of DNR treated WT
and Trib2-/- NH9 cells showed that the activation of cell
cycle inhibitors and regulators, including Cdkn1a (p21),
Cdkn1b (p27), INK4A (p16), ARF (p19) and Gadd45a/b,
was abolished or signiﬁcantly lowered in the absence of
Trib2. Indeed, levels of Cdkn1a (p21), INK4A (p16), ARF
(p19) and Gadd45b were lower in untreated Trib2-/- NH9
cells compared to the WT NH9 cells (Fig. 5a). Similar
results were observed following GFD (Figure S4A). Levels
of Cdk4, a positive regulator of cell cycle progression,
were higher in Trib2-/- NH9 cells compared to the WT
NH9 cells, at both steady state and upon GFD (Fig-
ure S4A), consistent with the highly proliferating pheno-
type of Trib2-/- NH9 cells. In addition, Trib2-/- NH9 cells
failed to upregulate Egr1 and Nfatc4 (apoptotic media-
tors), Jun and Fos (stress response TFs downstream of
MAPK signalling), mRNA in both vehicle control and
DNR treated samples (Figure S4B). These results
demonstrate that Trib2 expression is required in myeloid
leukaemia cells for efﬁcient activation of cell cycle check
point genes and DNA damage response signalling path-
ways. Assessment of key cell cycle checkpoint regulator
proteins by western blotting showed that induction of p-
p38 and p21 was impaired after 16, 20 and 24 h DNR
treatment in Trib2-/- NH9 compared to WT NH9 cells.
Importantly, the total protein levels of p38 level were
unaffected (Fig. 5b). Furthermore, mRNA levels of several
MAPKs genes, including MAPK3 (ERK1), MAPK9
(JNK2), MAPK11 (p38β), MAPK12 (p38γ), MAPK13
(p38δ), and theMKNK1 (MNK1), were signiﬁcantly lower
in Trib2-/- NH9 cells in response to DNR treatment
compared to the treated WT NH9 cells (Figure S4C).
Reduced activation of the MAPK p-p38 was also con-
ﬁrmed by ﬂow cytometry in WT and Trib2-/- NH9 cells in
response to DNR treatment (Fig. 5c, d). The fraction of p-
p38+ cells and the MFI of p-p38 (which correlates with
the number of p38 molecules activated per cell) were
signiﬁcantly lower in the Trib2-/- NH9 treated cells
compared to the WT NH9 cells. Levels of p-Chk1 and γ-
H2Ax (Ser139), key regulators of DNA damage response
signalling, were signiﬁcantly reduced in Trib2-/- NH9
treated cells compared to the WT NH9 treated cells
(Fig. 5c, d). Together these data demonstrate a role for
Trib2 as a major orchestrator of cell cycle check point and
stress signalling pathways in leukaemia, required for
efﬁcient activation of p38, Chk1 and γ-H2Ax, and stress-
induced p21 expression.
Trib2 deﬁciency enables propagation of drug resistant
leukaemic cells
To test whether the inappropriate stress response of
Trib2 deﬁcient leukaemia cells results in the propagation
of drug-resistant myeloid leukaemia cells, we performed
DNR washout (wo) experiments. WT and Trib2-/- NH9
cells were treated with the drug for 24 h, then washed and
replated in either LC or CFC assays (Fig. 6a). Trib2-/- NH9
(see ﬁgure on previous page)
Fig. 2 Trib2 deﬁciency accelerates cell proliferation promotes survival in NH9 leukaemic cells. a CTV assay of WT and Trib2-/- NH9 cells derived
from CFC3 (CFC, top) and CTV assay of WT and Trib2-/- MigR1/NH9 cells derived from 2 weeks in LC, in presence of recombinant SCF, IL3, IL6 (LC,
bottom). Samples were analysed by ﬂow cytometry at 96 h after staining with the CTV dye, and gated through GFP+ gates. Undivided, stained
control cells are shown in red (colcemid ctrl). Cell division gates are indicated and % of cells in each cell division for the transformed WT and Trib2-/-
NH9 cells is graphed. Data are representative of at least 3 independent experiments. b Growth curves (right) of WT and Trib2-/- NH9 cell lines, grown
in presence of IL3 (NH9 medium). In green and pink are the projected non-linear regression curves that best ﬁt the exponential growth models of WT
and Trib2-/- NH9 cells, respectively (calculated with the GraphPad software). c Growth rate and doubling time of WT and Trib2-/- NH9 cells, as
measured in B. Data shown are means of 3 independent experiments ± SD. *P < 0.05, using unpaired t-test. d–g Flow cytometric analysis of apoptotic
levels by means of AnnexinV/DNA DAPI staining in WT and Trib2-/- NH9 cell lines after GFD (d) and 24 h DNR treatment (f). f, g Graphed percentages
of Late Apoptotic cells (AnnexinV+/DNA DAPI+), at the indicated time points, as measured in (d) and (f), respectively. Data are representative of at
least 3 independent experiments, graphs show mean ± SD. *P ≤ 0.05, **P < 0.005, ***P < 0.001, using unpaired t-test
Salomé et al. Cell Death and Disease  (2018) 9:443 Page 6 of 17
Ofﬁcial journal of the Cell Death Differentiation Association
cells displayed reduced apoptotic rate in LC, and higher
clonogenic potential compared to the WT NH9 cells in
CFC (Fig. 6b-f). Moreover, cell surface marker analyses
revealed that drug resistant Trib2-/- NH9 cells continued
to express CD11b myeloid marker, higher levels of the
immature marker c-Kit (Fig. 6g, left and central panels),
and lower levels of the inﬂammatory surface marker Sca1
compared to WT NH9 cells in both untreated and drug
resistant cells (Fig. 6g, right panel). These data indicate
the Trib2 deﬁciency contributes to a drug resistant phe-
notype in myeloid leukaemia.
Re-expression of Trib2 reverts the drug resistant
phenotype of Trib2-deﬁcient myeloid leukaemia cells
To validate the drug resistant phenotype as a result of
the Trib2 deﬁciency, we reintroduced Trib2 protein
expression in the Trib2-/- NH9 cells. WT and Trib2-/-
NH9 were retrovirally transduced with NGFR and NGFR
Fig. 3 Trib2 deﬁcient myeloid leukaemia cells have impaired MAPKs activation. a Schematic of MAPK signalling cascade. b Western blot
analysis of MAPKs total and phosphorylated levels (ERK1-2 (Thr202/Tyr204), p38 (Thr180/Tyr182) and JNK (Thr183/Tyr185)) in WT and Trib2-/- NH9 cells.
Data are representative of at least 3 independent experiments. c Western blot analysis of MAPKs and AKT (Ser473) activation in WT and Trib2-/- NH9
cells after 1 h of GFD, followed by re-stimulation with IL3-containing medium (NH9 medium) for 0 and 15min. d Ans binds and activates the
p38 signalling pathway. Model of TRIB2-mediated regulation of MKK3/6 or p38 kinases (top). The p-p38 signal was measured by ﬂow cytometry
following stimulation of the WT and Trib2-/- NH9 cells with 25 and 50 ng/ml Ans, and normalised by DMSO treated control cells (bottom). Data shown
is average of 2 independent experiments ± SD, the genotype signiﬁcantly affects the result, P < 0.05 using two-way ANOVA
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Fig. 4 Trib2 deﬁcient myeloid leukaemia cells have an impaired cell cycle stress response. a Cell cycle ﬂow cytometric analysis by means of
Ki67/DNA staining in WT and Trib2-/- NH9 cells in response to DNR treatment. Plots are representative of 6 independent experiments with similar
trend. b Graphed percentages of G0, G1 and SG2M fractions, as measured in (A). Data are means ± SD of 3 independent experiments. *P < 0.05, using
unpaired t-test. c Flow cytometric analyses of the mitotic index in WT and Trib2-/- NH9 cells after 24 h DNR treatment, as measured by p-HH3/PI DNA
levels. d Graphed percentages, at the indicated time points, as measured (c). e Representative pictures of DAPI stained metaphase spreads from WT
and Trib2-/- NH9 cells after 24 h DNR treatment. f Graph showing percentages of mitotic spreads from WT and Trib2-/- NH9 cells after 24 h DNR/DMSO
treatment as measured e. Data are representative of at least 2 independent experiments, graphs show mean ± SD. *P < 0.05, **P < 0.005, using
unpaired t-test
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Trib2, andTrib2 mRNA or protein expression conﬁrmed
in NGFR+ sorted cells (Figure S5). NH9-expressing WT
NGFR, Trib2-/- NGFR, and Trib2-/- NGFR Trib2 were
treated with DNR and apoptosis and cell cycle proﬁles
were assessed. Our results showed that reintroduction of
Trib2 in the Trib2-/- NH9 cells increased apoptosis in
untreated and DNR treated cells to levels comparable with
WT NH9 cells (Fig. 7a). NH9-expressing Trib2-/- NGFR
Trib2 cells showed a higher proportion of cells in G0 and
less cells in G1 compared to Trib2-/- NGFR (Fig. 7b). This
was supported by the signiﬁcant decrease in the percen-
tage of p-HH3+ cells in NH9-expressing Trib2-/- NGFR
Trib2 treated cells compared to NH9-expressing Trib2-/-
NGFR treated cells (Fig. 7c). Together, these results
demonstrate that Trib2 expression is required for the
appropriate cell cycle stress response and the effective
killing of myeloid leukaemia cells.
Pharmacological activation of p38 reverts the drug
resistant phenotype of Trib2-deﬁcient myeloid leukaemia
cells
Next we tested whether pharmacological activation of
p38 by Ans could revert the DNR resistant phenotype of
the Trib2-/- NH9 cells similar to Trib2 re-expression
(Fig. 8a). Ans pre-treatment resulted in increased basal
and DNR-induced apoptosis in the Trib2-/- NH9 cells
(+Ans Trib2-/- NH9) (Fig. 8b top and bottom panels). In
addition, Ans pre-treatment restored drug-induced
expression of p38 target genes in the Trib2-/- NH9 cells
to levels comparable (INK4A, ARF) or higher (Cdkn1a,
Cdkn1b, Gadd45a) than those of the WT NH9 treated
cells (Fig. 8c). Overall, these data suggest that TRIB2
controls stress signalling responses via p38 activation. We
next tested the direct binding of Trib2 and p38 as a
mechanism for Trib2-mediated p38 regulation. Using a
co-immunoprecipitation (co-IP) assay in Hek293T cells
overexpressing myc-tagged Trib2 (PHMA Trib2) or
transfected with the empty control plasmid (PHMA) (S6),
we did not detect any binding between p38 and Trib2.
This result does not exclude the possibility that p38
MAPK and its upstream MAPKK activators could interact
with Trib2 in myeloid leukaemic cells transiently under
stress conditions.
Discussion
In this study, we investigated the impact of Trib2 deﬁ-
ciency in myeloid leukaemia. We demonstrate that Trib2
is not required for the initiation of myeloid leukaemia, but
is required for p38 and stress signalling, induction of cell
cycle checkpoint response and apoptosis. This tumour
suppressive role of the TRIB2-p38 axis is also supported
by the evidence that Trib2 deﬁciency accelerates the onset
of acute lymphoid leukaemia12. We show here the
defective stress response manifests a chemotherapy
resistant phenotype and a growth advantage to myeloid
leukaemia revealing, for the ﬁrst time, TRIB2 as a tumour
suppressor in myeloid leukaemia.
p38 is a regulator of key cell cycle regulators (p21, p16,
p19, GADD45), signalling molecules (Chk1, γH2Ax), TFs
(Egr1, Fos and Jun) which are inappropriately activated in
Trib2 deﬁcient leukaemia cells. These, and others, are
involved in proliferation, survival and stress response
pathways38–41, including the phosphatase CDC25(Ref7),
which is known to be regulated by Trib2. Therefore,
impaired p38 activation due to the absence of Trib2 most
likely accounts for the defective signalling response and
chemoresistant phenotype of myeloid leukaemia cell
(Fig. 8d). Indeed, using IL3 stimulation and the p38
pharmacological activator Ans, p38 phosphorylation/
activation was still lower in Trib2 deﬁcient cells compared
to treated WT NH9 cells, demonstrating that Trib2
functions in the activation of p38. The re-expression of
Trib2 or the activation of p38 in DNR treated Trib2
deﬁcient cells further conﬁrms the Trib2-p38 axis as a
regulator of cell cycle progression and damage signalling
pathways. As it is a pseudokinase, Trib2 would not lead to
phosphorylation of p38 upon binding (whether indirect or
direct), but act as a kinase inhibitor/competitive inhibitor/
allosteric regulator. It would be interesting to obtain
structural data on Trib2 necessary to support for this. To
date, no structural data for Trib2 is available.
Our data is consistent with the ﬁnding that Trib2
deletion does not impede MLL/AF9-driven myeloid leu-
kaemia17, as we did not observe any defect in the ability of
NH9 to transform Trib2 deﬁcient cells. Hoxa9-dependent
transactivation of the Trib2 promoter was shown to be
efﬁcient only in the presence of the cofactors Meis1 and
(see ﬁgure on previous page)
Fig. 5 Trib2 is required for activation of cell cycle inhibitors and check point regulators following drug treatment. a Trib2, Cdkn1a (p21),
Cdkn1b (p27), INK4A (p16), ARF (p19), Gadd45a and Gadd45b relative mRNA levels in WT and Trib2-/- NH9 cells after 16 h DNR treatment. Data are
representative of 2 (p16 and Gadd45a) or 3 (Trib2, p21, p27, p19 and Gadd45b) independent experiments with similar trend, graphs show mean of
technical replicates ± SD. *P < 0.05, **P < 0.005, ***P < 0.001 using unpaired t-test. b Western blot analysis of the indicated proteins in WT and Trib2-/-
NH9 cells in response to DNR treatment for the indicated time points. Data is representative of at least 3 independent experiments, with similar trend.
c Flow cytometric analysis of p-p38, p-Chk1 and γH2Ax levels in the live fraction of WT and Trib2-/- NH9 cells, after 24 h DNR treatment. Histograms are
representative of at least 3 independent experiments, with similar trend. d Graphed percentages (c) show average ± SD of three independent
measurements. MFI Median Fluorescent Intensity (indicated in the top right panel of the representative histograms). *P < 0.05, **P < 0.005, ***P <
0.001 using unpaired t-test
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Pbx323,24. Overexpression of NH9, enhancing self-renewal
potential of normal cells, did not induce Trib2 gene
upregulation in WT HSPCs. Moreover, no differences
were observed in Hox genes expression in presence or
absence of Trib2, suggesting that Trib2 cooperativity in
myeloid leukaemia18 is independent on the HOX tran-
scriptional program. This is supported by the observation
that cooperating lesions in myeloid leukaemia usually
affect non-redundant pathways, e.g., proliferation/survival
and self-renewal/differentiation42. Indeed, we have
demonstrated that Trib2 modulates the expression or
activation of several signalling molecules and cell cycle
inhibitors, whereas NH9 confers aberrant self-renewal
potential to the cells.
We demonstrated that Trib2 is required in response to
stress to efﬁciently inhibit cell cycle progression and
mitosis, in order to prevent the propagation of damaged
cells. These data suggest that Trib2 may be an important
regulator in myeloid leukaemia drug resistance and
relapse. We showed that Trib2 is transcriptionally
upregulated in the WT myeloid leukaemia cells after
either starvation or genotoxic challenge. Our results are
in line with previous studies, reporting TRIB2 upregu-
lation in response to survival factor withdrawal in pri-
mary T-cells and erythroleukaemia cells43, miR155
induction in acute myeloid leukaemia cells44 and cis-
platin treatment in ovarian cancer cells6, which all
associated with activation of the apoptotic pathway.
Conversely, ectopic or intrinsic high TRIB2 expression
confers chemoresistance in solid cancers and leukaemia,
by modulating the AKT/FOXO/p53 signalling path-
way45 and upregulation of BCL2 expression46. There-
fore, similar to other renowned cancer related proteins
(e.g. E2Fs, p21, GADD45A, MYC and RUNX1), Trib2
obeys the Goldilocks principle in cancer biology; too
little or too much are both pro-tumorigenic. Data from
us and others would conclude that Trib2 exerts a dual
role in myeloid leukaemia and other cancers (e.g., T cell
leukaemia, liver), in a stage- and context-speciﬁc
manner.
Summarising, this work identiﬁed a novel Trib2-p38
regulatory pathway important for cell cycle checkpoint
and stress responses, with implications on drug resistance
and relapse in myeloid leukaemia (Fig. 8d).
Materials and methods
Mice
Trib2 knock out mice (B6; 129S5-Trib2tm1Lex, referred
to as Trib2-/-), backcrossed onto C57B6 as previously
described12, were housed in the university of Glasgow. All
animals were handled in accordance with good animal
practice as deﬁned by the Animals (Scientiﬁc Procedures)
Act 1986. Mice used in the study were from age matched
adult (7-14 week old) WT and Trib2-/- mice of either sex.
Primary cell culture, transduction and generation of WT
and Trib2-/- NH9 cell lines
Retroviral supernatants were generated by transient
transfection of Hek293T cells with the retroviral con-
structs (together with pCMV-Gag-Pol packaging vector
and pHIT123 envelope vector) with the calcium-
phosphate method and titered with NIH-3T3 cell as
previously described15. For transduction experiments,
total bone marrow cells were isolated and were enriched
for c-Kit expression, using anti-CD117 (c-Kit) microbeads
and MS MACS columns (Miltenyi Biotec) according to
manufacturer’s instructions. c-Kit+ cells are an enriched
HSPC population. They were cultured o/n in prestimu-
lation medium (DMEM, 15% FBS, 2 mM L-glutamine,
100 U/mL Penicillin/Streptomycin (Pen/Strep), 10 ng/ml
IL3, 10 ng/ml IL6, 100 ng/ml SCF). WT and Trib2-/-
HSPCs were transduced with MigR1 or MigR1 NH9 GFP
tagged retroviral vectors31. WT and Trib2-/- NH9
immortalized lines were generated by expansion in liquid
culture (LC) in prestimulation medium for 9 weeks.
Afterwards, the culture was continued in NH9 medium
(DMEM, 10% FBS, 10% WEHI-3B conditioned medium, 2
mM L-glutamine, 100 U/mL Pen/Strep). NH9 samples
outgrew MigR1 controls and 100% GFP+NH9 cells were
immortalised. The growth of the NH9 cell lines was
monitored by trypan blue counts. The cells were routinely
tested for mycoplasma contamination before and after
freezing and thawing. For growth factor deprivation
(GFD) experiments, NH9 cell lines were seeded at 0.1 ×
106 cells/ml 24 h before starvation. The cells were incu-
bated in starvation medium (DMEM, 2 mM L-glutamine,
100 U/ml Pen/Strep), for the indicated time points. For
daunorubicin (DNR) and anisomycin (Ans) treatment
experiments, NH9 cell lines were seeded at 0.2 × 106 cells/
(see ﬁgure on previous page)
Fig. 6 Trib2-/- NH9 cells are more resistant to DNR-dependent apoptosis after removal of the drug. a Schematic showing experimental
strategy of the DNR wo experiments in LC or IL3-supplemented MC. b Apoptosis analysis of the WT and Trib2-/- NH9 cells after 24 h DMSO/DNR
treatment, and at 24, 48 h and 7 days after drug wo. c Day 7 and d day 5 colony pictures (4×) of WT and Trib2-/- NH9 samples treated with DMSO/DNR
for 24 h and plated in MC, after wo, at the indicated cell range, in independent experiments. e, f Colony counts at day 7, as per experiment in (c and
d), respectively. Graphs show mean of duplicate (c, e) or triplicates (d, f) cultures ± SD. *P < 0.05, **P < 0.005, ***P < 0.001 using unpaired t-test. g Flow
cytometric analysis of the indicated myeloid and primitive surface markers of WT and Trib2-/- NH9 cells in (d, f), grown in MC for 7 days, after removal
of the drug. Graphs show mean of triplicate cultures ± SD. *P < 0.05, **P < 0.005, ***P < 0.001 using unpaired t-test
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ml 24 h before treatment with either 50 nM DNR or 25
and 50 ng/ml Ans or DMSO as vehicle control. The DNR
inhibitory concentration 50 (IC50) was determined in WT
NH9 overexpressing cells (46.07 nM) (S3A). Cells trans-
ductions were performed centrifuging 2–5 × 106 cells/ml
cells with the required vectors for 90min at 1290xg in
either prestimulation medium (HSPCs) or NH9 medium
(NH9 cell lines), supplemented with 4 µg/ml of polybrene.
Colony forming cell (CFC) assay
For CFC assays of freshly transduced HSPCs (isolated
by c-Kit enrichment), equal numbers of sorted GFP-
expressing cells (0.5 or 10 × 103) were seeded in Metho-
Cult™ GFM3434 (Stem Cell Technologies) (MC) medium,
containing 15% FBS, 1% BSA, insulin (10 μg/ml), trans-
ferrin (200 μg/ml), IL3 (10 ng/ml), IL6 (10 ng/ml), SCF
(50 ng/ml) and Erythropoietin (3 U/mll), and supple-
mented with Pen/Strep (100 U/ml). For DNR wash out
CFC assays, equal numbers of WT and Trib2-/- NH9 cells
(0.1 or 30 × 103) were treated with DNR for 24 h and
remaining cells plated in MC medium (M3231, Stem Cell
Technologies), containing 30% FBS and 1% BSA, supple-
mented with IL3 (10 ng/ml) and Pen/Strep 100 U/ml.
Colonies were scored after 1 to 2 weeks.
Fluorescent activated cell sorting (FACS) analyses
Flow cytometry experiments were performed using BD
FACSCanto™ II and BD FACSAria™ (BD biosciences, UK).
Cell trace™ violet (CTV, Invitrogen) staining was performed
following manufacturer instructions and the ﬂuorescent
signal assessed in the proliferating samples after 4 days of
culture. Cells treated for 24 h with 100 ng/ml demecolcine
solution (Sigma) were used as undivided control (colcemid
control) and used to calculate the undivided generation
peak (division 0). Apoptosis was measured by AnnexinV
(eBioscience) / 4′,6-diamidino-2-phenylindole (DAPI,
Sigma) staining, performed in HBSS solution (Gibco). For
staining of the intracellular antigens, the cells of interest
were ﬁxed and permeabilised using the BD Cytoﬁx/Cyto-
perm™ Fixation/Permeabilization Kit (BD biosciences),
subsequently incubated with anti-Ki67 (eBioscience), anti-
phospho(p)-p38 (eBioscience), anti-phospho(p)-Chk1 (New
England Biolab) or anti-γH2Ax (BD Biosciences) antibodies
(Table S1). For mitotic index measurement, the cells were
ﬁxed using the BD Fixation/Permeabilization solution (BD
biosciences) and permeabilised with 90% methanol, fol-
lowed by incubation with anti-phospho-Histone H3 (p-
HH3) antibody (Cell Signaling Technology, Table S1). DNA
staining was performed on fresh or ﬁxed samples using PI/
RNase Staining Solution (BD biosciences), or DAPI, for cell
cycle or viability analyses. For surface antigens detection,
fresh samples were incubated with anti-CD3, anti-CD4,
anti-CD8, anti-CD19, anti-B220, anti-Ter119, anti-Gr1,
anti-CD127 (IL7R), anti-CD34, anti-CD16/32, anti-CD11b,
anti-CD117(c-Kit) and anti-Sca1 antibodies (eBioscience),
and DAPI+ dead cells exclusion was performed. In all ﬂow
cytometry analyses, the desired populations were gated
through FSC-Area/SSC-Area and doublets were excluded
based on FSC-Height/FSC-Area.
Real time PCR (RT-PCR)
Up to 1 µg of total RNA was reverse transcribed with the
high capacity cDNA reverse transcription kit (Applied
Biosystems), following manufacturers’ instruction. In case
of low cell number samples, Speciﬁc Target Ampliﬁcation
(STA) reaction was performed with the Qiagen® Multiplex
PCR Kit (Qiagen), following manufacturers’ instructions.
RT-PCR was performed using the Fast SYBR™ Green 2×
Master Mix (Applied Biosystems), according to manu-
facturers’ instruction. All primers, listed in Table S2, were
designed to target murine sequences. Failed reactions/
outliers were excluded from the analyses.
Co-immunoprecipitation (Co-IP)
Hek293T cells were transiently transfected with the myc-
tagged PHMA Trib2 or PHMA control vectors as pre-
viously described15. The transfected cells were harvested at
24 h and whole cell lysates were prepared using ice-cold
Hepes buffer (50mM Hepes pH 7.4, 150mM NaCl, 1 mM
EDTA, 0.5% NP-40, 5% glycerol, with protease and phos-
phatase inhibitors). Crosslinking was performed using
dithiobis-succinimidylpropionate (DSP) (Thermo Fisher
Scientiﬁc) at a concentration of 1.5mM, and the reaction
quenched using Tris (pH 7.4) (50mM). One milligram of
precleared lysates were incubated with Myc9E10 antibody
(Santa Cruz Biotechnology) or normal mouse IgG over-
night at 4 °C, followed by incubation with Protein A/G
UltraLink™ Resin (Thermo Fisher Scientiﬁc) for 1.5 h at 4 °
(see ﬁgure on previous page)
Fig. 7 Re-introduction of Trib2 in Trib2-/- NH9 cells re-establishes an apoptotic and cell cycle response to drug treatment. Flow cytometric
analysis of apoptotic levels by means of AnnexinV/DNA DAPI (a), Cell cycle Ki67/DNA DAPI (b), and mitotic index by means of p-HH3/DNA DAPI
staining (c) in WT and Trib2-/- NH9 MigR1 NGFR/NGFR Trib2 transduced cells, after 24 h DNR treatment. d Shows graphed percentages of Live
(AnnexinV-/DNA DAPI-) and Late Apoptotic (AnnexinV+/DNA DAPI+) cells, as measured (a). Data are representative of 4 independent experiments,
graphs show mean ± SD. *P < 0.05, **P < 0.005, ***P < 0.001, using unpaired t-test. e Graphed percentages of p-HH3+ cells, as measured (c). Data are
representative of 2 independent experiments, graphs show mean ± SD. **P < 0.005 using unpaired t-test
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C. The samples were washed in Tris buffer (50mM Tris
pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% NP-40, 5%
glycerol, with protease and phosphatase inhibitors), eluted
in Laemmli buffer and analysed by western blotting.
Western Blotting
Whole cell lysates were prepared using ice-cold modiﬁed
RIPA buffer (50mM Tris, pH 8.0, containing 0.5% NP-40,
0.25% sodium deoxycholate, 150mM NaCl, 1mM EDTA,
with protease and phosphatase inhibitors). Up to 25 µg of
protein samples were resolved on hand-casted SDS-PAGE
gels, transferred to 0.45 μm nitrocellulose membrane
(Whatman) and analysed by immunoblotting with the anti-
bodies listed in Table S3. SuperSignal™ West Pico or Femto
Chemoluminescent Substrates (Thermo Fisher Scientiﬁc)
were used for signal detection on CL-XPosure™ radiography
ﬁlms. The ﬁlms were developed using the Medical ﬁlm
processor SRX-101A (Konika Minolta, Tokyo, Japan).
Metaphase spreads
WT and Trib2-/- NH9 cells were seeded at 0.2 × 106 cells/
ml and treated with DNR/ DMSO from WT and Trib2-/-
NH9 cells after 24h DNR treatment from WT and Trib2-/-
NH9 cells after 24h DNR treatment for 24h. Demecolcine
solution (Sigma) was added to the cell suspension (100 ng/
ml) 45min prior the end of the treatment. The cells were
incubated at 37 °C for 15min in 75mM KCl (swelling). The
cell were ﬁxed in 3:1 methanol:acetic acid. Fixed cells were
dropped on microscope slides and let dry at RT. Mounting
medium with DAPI (Vector shield) was applied to each
sample. The slides were examined at an Axio Imager M1
Epiﬂuorescence and Brightﬁeld Microscope (Zeiss) and
pictures captured to show representative mitotic cells
(Axio Vision software).
Statistics
Graphs and statistical analyses were performed using
GraphPad Prism 5 (GraphPad Software, La Jolla Cali-
fornia USA). Flow cytometry data were analysed using
FlowJo (Tree Star, Ashland OR USA). Unpaired, two-
tailed Student’s t-test was used to test statistical sig-
niﬁcance whenever comparing two experimental groups
with similar variance. Two-way ANOVA was used to
evaluate the effect of the genotype (WT and Trib2-/-) on the
fold change p-p38 expression over two doses of Ans sti-
mulation. The statistical test used, the P value (*P < 0.05,
**P < 0.005, ***P < 0.001) and the number of times each
experiment was biologically and technically replicated was
indicated in the related ﬁgure legends and graphs.
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